Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.8 CHF | +5.90% | +25.71% | +77.78% |
Business Summary
Number of employees: 22
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Drugs
100.0
%
| 6 | 100.0 % | 9 | 100.0 % | +43.85% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Italy & United States
100.0
%
| 6 | 100.0 % | 9 | 100.0 % | +43.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 16-10-31 |
Ravi Anand
CTO | Chief Tech/Sci/R&D Officer | 67 | 04-12-31 |
Laura Faravelli
PRN | Corporate Officer/Principal | - | 18-12-31 |
Dennis Dionne
PRN | Corporate Officer/Principal | - | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,631,834 | 17,069,414 ( 91.61 %) | 0 | 91.61 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+67.88% | 170M | |
-3.79% | 87.06B | |
+2.76% | 40.25B | |
-17.49% | 31.09B | |
+54.82% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- NWRN Stock
- Company Newron Pharmaceuticals S.p.A.